[11:48 PM, 4/28/2026] +93 79 666 5158: EMPATIN-H Tablets
Generic Name:
Empagliflozin 25 mg + Linagliptin 5 mg
Therapeutic Group:
Antidiabetic Combination
Drug Category:
SGLT2 Inhibitor + DPP-4 Inhibitor
Content / Composition:
Each film-coated tablet contains:
Empagliflozin …………………………… 25 mg
Linagliptin ……………………………… 5 mg
Excipients ……………………………… q.s.
Indications:
EMPATIN-H is indicated for:
Type 2 Diabetes Mellitus
Improvement of glycemic control in adults inadequately controlled on monotherapy
Reduction of cardiovascular risk in patients with Type 2 Diabetes
Renal protection in diabetic patients (as part of comprehensive care)
Dosage:
One tablet once daily
Can be taken with or without food
Dose adjustment based on renal function and clinical response
As directed by the physician
Contraindications:…
[11:50 PM, 4/28/2026] +93 79 666 5158: EMPATIN-H Tablets
Generic Name:
Empagliflozin 10 mg + Linagliptin 5 mg
Therapeutic Group:
Antidiabetic Combination
Drug Category:
SGLT2 Inhibitor + DPP-4 Inhibitor
Content / Composition:
Each film-coated tablet contains:
Empagliflozin …………………………… 10 mg
Linagliptin ……………………………… 5 mg
Excipients ……………………………… q.s.
Indications:
EMPATIN-H is indicated for:
Type 2 Diabetes Mellitus
Improvement of glycemic control in adults inadequately controlled on monotherapy
Reduction of cardiovascular risk in diabetic patients
Support of renal protection as part of comprehensive diabetes care
Dosage:
One tablet once daily
Can be taken with or without food
Dose adjustment based on renal function and clinical response
As directed by the physician
Contraindications:
Hypersensitivi…
[11:51 PM, 4/28/2026] +93 79 666 5158: SITA-H Tablets
Generic Name:
Sitagliptin 50 mg + Metformin Hydrochloride 1000 mg
Therapeutic Group:
Antidiabetic Combination
Drug Category:
DPP-4 Inhibitor + Biguanide
Content / Composition:
Each film-coated tablet contains:
Sitagliptin ……………………………… 50 mg
Metformin Hydrochloride ………… 1000 mg
Excipients ……………………………… q.s.
Indications:
SITA-H is indicated for:
Type 2 Diabetes Mellitus
Patients inadequately controlled with metformin alone or other oral agents
Improvement of glycemic control (fasting and postprandial glucose)
Combination therapy to enhance insulin secretion and reduce hepatic glucose production
Dosage:
One tablet twice daily with meals (or as directed by physician)
Dose should be individualized based on glycemic response
Gradual titration recomme…
[11:53 PM, 4/28/2026] +93 79 666 5158: SITA-H Tablets
Generic Name:
Sitagliptin 50 mg + Metformin Hydrochloride 850 mg
Therapeutic Group:
Antidiabetic Combination
Drug Category:
DPP-4 Inhibitor + Biguanide
Content / Composition:
Each film-coated tablet contains:
Sitagliptin ……………………………… 50 mg
Metformin Hydrochloride ………… 850 mg
Excipients ……………………………… q.s.
Indications:
SITA-H is indicated for:
Type 2 Diabetes Mellitus
Patients inadequately controlled with metformin or other oral antidiabetics
Improvement of glycemic control (fasting and postprandial glucose)
Combination therapy to enhance insulin secretion and reduce hepatic glucose production
Dosage:
One tablet twice daily with meals (or as directed by physician)
Dose should be individualized based on glycemic response
Gradual titration recommen…
[11:56 PM, 4/28/2026] +93 79 666 5158: SITA-H Tablets
Generic Name:
Sitagliptin 50 mg + Metformin Hydrochloride 500 mg
Therapeutic Group:
Antidiabetic Combination
Drug Category:
DPP-4 Inhibitor + Biguanide
Content / Composition:
Each film-coated tablet contains:
Sitagliptin ……………………………… 50 mg
Metformin Hydrochloride ………… 500 mg
Excipients ……………………………… q.s.
Indications:
SITA-H is indicated for:
Type 2 Diabetes Mellitus
Patients inadequately controlled on metformin or other oral antidiabetic agents
Improvement of glycemic control (fasting and postprandial glucose)
Combination therapy to enhance insulin secretion and reduce hepatic glucose production
Dosage:
One tablet twice daily with meals (or as directed by physician)
Dose should be individualized based on glycemic response
Gradual titration reco…
[11:57 PM, 4/28/2026] +93 79 666 5158: DAFA-H 5 mg Tablets
Generic Name:
Dapagliflozin 5 mg
Therapeutic Group:
Antidiabetic Agent
Drug Category:
SGLT2 Inhibitor (Sodium-Glucose Co-Transporter 2 Inhibitor)
Content / Composition:
Each film-coated tablet contains:
Dapagliflozin …………………………… 5 mg
Excipients ……………………………… q.s.
Indications:
DAFA-H is indicated for:
Type 2 Diabetes Mellitus
Improvement of glycemic control as monotherapy or in combination
Reduction of cardiovascular risk in patients with diabetes
Renal protection in diabetic patients
Adjunct therapy with diet and exercise
Dosage:
Usual dose: 5 mg once daily
May be increased to 10 mg once daily based on response
Taken once daily at any time, with or without food
As directed by the physician
Contraindications:
Hypersensitivity to dapagliflozin
Type 1 Diabetes Mellitus
Diabetic ketoacidosis
Severe renal impairment (eGFR <30 mL/min)
Pregnancy and lactation
Administration:
Administer orally with water
Maintain adequate hydration
Take at the same time each day
Drug Interactions:
Diuretics may increase risk of dehydration and hypotension
Increased risk of hypoglycemia when combined with insulin or sulfonylureas
Caution with antihypertensive medications
Compatibility:
Suitable for combination with metformin, insulin, or other oral antidiabetic agents
Compatible with long-term diabetes management protocols
Stability / Storage:
Store below 25°C
Protect from light, heat, and moisture
Keep out of reach of children
Precautions:
Risk of dehydration and hypotension
Monitor renal function regularly
Increased risk of genital and urinary tract infections
Educate patients about signs of ketoacidosis (rare but serious)
Use cautiously in elderly patients
Side Effects:
Common:
Increased urination
Genital infections
Urinary tract infections
Thirst
Uncommon:
Dizziness
Hypotension
Dehydration
Serious (Rare):
Diabetic ketoacidosis
Acute kidney injury
Severe infections
Important Note:
DAFA-H is an SGLT2 inhibitor used for glycemic control and offers cardiovascular and renal benefits. It should be used under medical supervision. This information is intended for healthcare professionals and educational purposes only.

DAFA-H 10 mg Tablets
Generic Name:
Dapagliflozin 10 mg
Therapeutic Group:
Antidiabetic Agents
Drug Category:
SGLT2 Inhibitor (Sodium-Glucose Co-Transporter 2 Inhibitor)
Content / Composition:
Each film-coated tablet contains:
Dapagliflozin …………………………… 10 mg
Excipients ……………………………… q.s.
Indications:
DAFA-H is indicated for:
Type 2 Diabetes Mellitus
Improvement of glycemic control as monotherapy or combination therapy
Reduction of cardiovascular events in high-risk patients
Chronic kidney disease (CKD) management in diabetic patients
Adjunct to diet and exercise
Dosage:
Recommended dose: 10 mg once daily
Taken once daily at any time of the day
Can be taken with or without food
Dose adjustment may be required based on renal function
As directed by the physician
Contraindications:
Hypersensitivity to dapagliflozin or any component
Type 1 Diabetes Mellitus
Diabetic ketoacidosis
Severe renal impairment (eGFR <30 mL/min/1.73 m²)
Pregnancy and breastfeeding
Administration:
Oral administration with sufficient water
Maintain adequate hydration
Preferably taken at the same time daily
Drug Interactions:
Diuretics: Increased risk of dehydration and hypotension
Insulin or sulfonylureas: Increased risk of hypoglycemia
Antihypertensives: May enhance hypotensive effect
Monitor renal function when used with nephrotoxic drugs
Compatibility:
Can be safely combined with metformin, DPP-4 inhibitors, insulin, and other antidiabetic agents
Suitable for long-term diabetes management strategies
Stability / Storage:
Store below 25°C
Protect from moisture, light, and heat
Keep out of reach of children
Precautions:
Risk of dehydration and hypotension
Monitor kidney function before and during treatment
Increased risk of urinary and genital infections
Rare risk of diabetic ketoacidosis (even with normal glucose levels)
Use with caution in elderly patients
Side Effects:
Common:
Increased urination
Genital fungal infections
Urinary tract infections
Thirst
Uncommon:
Dizziness
Hypotension
Dehydration
Serious (Rare):
Diabetic ketoacidosis
Acute kidney injury
Severe urinary/genital infections
Clinical Note:
DAFA-H (Dapagliflozin) is an advanced SGLT2 inhibitor that not only improves glycemic control but also provides significant cardiovascular and renal protection benefits. It is widely recommended in modern diabetes management guidelines.

DAFA-M-H Tablets
Generic Name:
Dapagliflozin 10 mg + Metformin Hydrochloride 500 mg
Therapeutic Group:
Antidiabetic Agents
Drug Category:
SGLT2 Inhibitor + Biguanide Combination
Content / Composition:
Each film-coated tablet contains:
Dapagliflozin …………………………… 10 mg
Metformin Hydrochloride ………… 500 mg
Excipients ……………………………… q.s.
Indications:
DAFA-M-H is indicated for:
Type 2 Diabetes Mellitus
Patients inadequately controlled on metformin alone
Combination therapy to improve glycemic control
Reduction of cardiovascular risk in diabetic patients
Renal protection in diabetic nephropathy
Dosage:
Usual dose: One tablet once or twice daily
Recommended to be taken with meals (to reduce GI side effects of metformin)
Dose adjustment based on patient condition and renal function
As directed by the physician
Contraindications:
Hypersensitivity to dapagliflozin or metformin
Type 1 Diabetes Mellitus
Diabetic ketoacidosis
Severe renal impairment (eGFR <30 mL/min/1.73 m²)
Severe hepatic impairment
Conditions predisposing to lactic acidosis
Pregnancy and lactation
Administration:
Oral administration with meals
Swallow whole with water
Do not crush or chew
Maintain proper hydration
Drug Interactions:
Insulin / Sulfonylureas → Increased risk of hypoglycemia
Diuretics → Increased dehydration risk
Alcohol → Increased risk of lactic acidosis
Cationic drugs (e.g., cimetidine) → May affect metformin elimination
Nephrotoxic drugs → Monitor renal function
Compatibility:
Compatible with insulin, DPP-4 inhibitors, GLP-1 analogs
Suitable for combination diabetes therapy
Effective dual mechanism (renal glucose excretion + reduced hepatic glucose production)
Stability / Storage:
Store below 25°C
Protect from moisture, light, and heat
Keep out of reach of children
Precautions:
Monitor renal function regularly
Risk of lactic acidosis (metformin component)
Risk of dehydration and hypotension (dapagliflozin)
Increased risk of urinary/genital infections
Temporarily discontinue before major surgery or contrast imaging
Use cautiously in elderly patients
Side Effects:
Common:
Gastrointestinal upset (nausea, diarrhea)
Increased urination
Genital infections
Headache
Uncommon:
Dizziness
Hypotension
Vitamin B12 deficiency (long-term metformin use)
Serious (Rare):
Lactic acidosis
Diabetic ketoacidosis
Acute kidney injury
Clinical Note:
DAFA-M-H provides a dual mechanism of action by combining dapagliflozin (renal glucose excretion) and metformin (hepatic glucose suppression), offering superior glycemic control along with cardiovascular and renal benefits. It is widely used in modern diabetes management protocols.

FLAVIDO™ Tablets
Generic Name:
Cinnarizine 20 mg + Domperidone 15 mg
Therapeutic Group:
Anti-Vertigo & Antiemetic Agents
Drug Category:
Calcium Channel Blocker (Cinnarizine) + Dopamine Antagonist (Domperidone)
Content / Composition:
Each tablet contains:
Cinnarizine …………………………… 20 mg
Domperidone ………………………… 15 mg
Excipients ……………………………… q.s.
Indications:
FLAVIDO is indicated for:
Vertigo (vestibular disorders)
Nausea and vomiting
Motion sickness
Ménière’s disease
Balance disorders
Gastrointestinal-related nausea
Dosage:
Adults: 1 tablet 2–3 times daily
Preferably taken before meals
Dose may be adjusted based on severity
For motion sickness: take 1 tablet 1–2 hours before travel
As directed by the physician
Contraindications:
Hypersensitivity to cinnarizine or domperidone
Prolactin-secreting tumors (prolactinoma)
Severe hepatic impairment
Gastrointestinal obstruction or bleeding
Known cardiac arrhythmias or prolonged QT interval
Concomitant use with strong CYP3A4 inhibitors
Administration:
Oral use with water
Best taken before meals
Do not exceed recommended dose
Drug Interactions:
CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) → Increased domperidone levels
CNS depressants → Enhanced sedative effect
Anticholinergics → May reduce effect of cinnarizine
QT-prolonging drugs → Increased cardiac risk
Compatibility:
Can be used with anti-vertigo and antiemetic therapies
Suitable for short-term and symptomatic management
Dual-action provides central and peripheral symptom control
Stability / Storage:
Store below 25°C
Protect from moisture and light
Keep out of reach of children
Precautions:
Use cautiously in elderly patients
May cause drowsiness — avoid driving or operating machinery
Monitor cardiac patients carefully
Avoid long-term use without medical supervision
Use cautiously in Parkinson’s disease (cinnarizine effect)
Side Effects:
Common:
Drowsiness
Dry mouth
Fatigue
Gastrointestinal discomfort
Uncommon:
Weight gain
Headache
Dizziness
Serious (Rare):
Extrapyramidal symptoms
Cardiac arrhythmias (QT prolongation)
Hyperprolactinemia (domperidone-related)
Clinical Note:
FLAVIDO™ offers a dual-action mechanism combining vestibular suppression (cinnarizine) and antiemetic activity (domperidone), making it highly effective for managing vertigo, motion sickness, and nausea with rapid symptomatic relief.

BACLOF-H Tablets
Generic Name:
Baclofen 10 mg
Therapeutic Group:
Skeletal Muscle Relaxants
Drug Category:
GABA-B Receptor Agonist (Centrally Acting Muscle Relaxant)
Content / Composition:
Each tablet contains:
Baclofen ……………………………… 10 mg
Excipients …………………………… q.s.
Indications:
BACLOF-H is indicated for:
Muscle spasticity of spinal origin
Multiple sclerosis–related spasticity
Spinal cord injuries
Cerebral palsy
Muscle stiffness and spasms
Neuromuscular disorders
Dosage:
Initial dose: 5 mg three times daily
Gradually increase every 3–7 days based on response
Usual maintenance dose: 30–80 mg per day in divided doses
Maximum dose: As per physician recommendation
Do not discontinue abruptly
As directed by the physician
Contraindications:
Hypersensitivity to baclofen
History of severe renal impairment (without dose adjustment)
Use cautiously in epilepsy patients
Peptic ulcer disease (with caution)
Administration:
Oral use with or after food
Swallow with water
Gradual dose titration required
Gradual withdrawal recommended to avoid withdrawal symptoms
Drug Interactions:
CNS depressants (e.g., benzodiazepines, alcohol) → Increased sedation
Antihypertensives → Enhanced hypotensive effect
Antidepressants → May enhance CNS depression
Levodopa → Risk of hallucinations and confusion
Compatibility:
Can be used with physiotherapy and rehabilitation programs
Suitable for long-term management under medical supervision
Effective in combination with other neuromuscular therapies
Stability / Storage:
Store below 25°C
Protect from moisture and light
Keep out of reach of children
Precautions:
Avoid sudden discontinuation (risk of withdrawal, seizures, hallucinations)
Use cautiously in renal impairment
May cause sedation — avoid driving or machinery
Monitor elderly patients closely
Use cautiously in psychiatric disorders
Side Effects:
Common:
Drowsiness
Dizziness
Weakness
Fatigue
Uncommon:
Hypotension
Confusion
Nausea
Serious (Rare):
Respiratory depression
Seizures (withdrawal-related)
Hallucinations
Bradycardia
Clinical Note:
BACLOF-H (Baclofen) acts centrally on GABA-B receptors to reduce muscle spasticity and improve mobility. It is widely used in neurological conditions requiring long-term spasm control and neuromuscular stabilization.

SBTRAM Tablets
Generic Name:
Tramadol Hydrochloride 37.5 mg + Paracetamol 325 mg
Therapeutic Group:
Analgesics (Pain Management)
Drug Category:
Opioid Analgesic + Non-Opioid Analgesic Combination
Content / Composition:
Each tablet contains:
Tramadol Hydrochloride ………… 37.5 mg
Paracetamol (Acetaminophen) … 325 mg
Excipients ……………………………… q.s.
Indications:
SBTRAM is indicated for:
Moderate to severe pain
Musculoskeletal pain
Post-operative pain
Dental pain
Trauma-related pain
Chronic pain conditions (under medical supervision)
Dosage:
Adults: 1–2 tablets every 4–6 hours as needed
Maximum daily dose:
Tramadol: 300 mg/day
Paracetamol: 4000 mg/day
Use the lowest effective dose for the shortest duration
As directed by the physician
Contraindications:
Hypersensitivity to tramadol, paracetamol, or opioids
Severe respiratory depression
Acute intoxication with alcohol, hypnotics, or CNS depressants
Severe hepatic impairment
Epilepsy (uncontrolled)
Children under 12 years
Use with MAO inhibitors (within 14 days)
Administration:
Oral use with or without food
Swallow with water
Do not exceed recommended dose
Avoid alcohol during treatment
Drug Interactions:
CNS depressants → Increased sedation and respiratory depression
SSRIs / SNRIs → Risk of serotonin syndrome
MAO inhibitors → Severe interactions
Warfarin → Increased bleeding risk
Hepatotoxic drugs → Increased liver risk (paracetamol)
Compatibility:
Suitable for short-term pain management
Can be used with anti-inflammatory therapies (under supervision)
Effective multimodal analgesia
Stability / Storage:
Store below 25°C
Protect from moisture and light
Keep out of reach of children
Precautions:
Risk of dependence and abuse (tramadol component)
Use cautiously in elderly patients
Monitor liver function (paracetamol)
Avoid long-term use without supervision
Risk of respiratory depression
Use caution in patients with seizure disorders
Side Effects:
Common:
Nausea
Dizziness
Drowsiness
Constipation
Uncommon:
Sweating
Dry mouth
Headache
Serious (Rare):
Respiratory depression
Seizures
Serotonin syndrome
Liver toxicity (overdose)
Clinical Note:
SBTRAM provides dual-action pain relief by combining the central opioid effect of tramadol with the peripheral analgesic action of paracetamol, offering effective and rapid relief in moderate to severe pain conditions.

ETDOL-P Tablets
Generic Name:
Etoricoxib 60 mg + Paracetamol 325 mg
Therapeutic Group:
Analgesic & Anti-inflammatory
Drug Category:
Selective COX-2 Inhibitor (NSAID) + Non-Opioid Analgesic
Content / Composition:
Each film-coated tablet contains:
Etoricoxib ………………… 60 mg
Paracetamol …………… 325 mg
Excipients ………………… q.s.
Indications:
ETDOL-P is indicated for:
Osteoarthritis
Rheumatoid arthritis
Ankylosing spondylitis
Acute musculoskeletal pain
Dental pain
Post-operative pain
Dysmenorrhea (menstrual pain)
Acute gouty arthritis (pain management)
Dosage:
Adults: 1 tablet once daily or as directed by physician
In acute pain: may be used short-term under supervision
Maximum duration: use lowest effective dose for shortest time
Contraindications:
Hypersensitivity to etoricoxib, paracetamol, or NSAIDs
Active peptic ulcer or gastrointestinal bleeding
Severe hepatic impairment
Severe renal impairment
Established cardiovascular disease (e.g., ischemic heart disease, stroke)
Uncontrolled hypertension
Pregnancy (especially 3rd trimester)
Administration:
Oral use, with or without food
Swallow whole with water
Do not exceed recommended dose
Avoid concurrent use with other NSAIDs
Drug Interactions:
Anticoagulants (e.g., warfarin) → Increased bleeding risk
ACE inhibitors / ARBs → Reduced renal function
Diuretics → Reduced efficacy, risk of kidney issues
Other NSAIDs → Increased GI risk
Hepatotoxic drugs → Increased liver risk (paracetamol)
Compatibility:
Suitable for inflammatory pain conditions
Can be combined with gastroprotective agents if needed
Effective for both pain and inflammation control
Stability / Storage:
Store below 25°C
Protect from light and moisture
Keep out of reach of children
Precautions:
Increased cardiovascular risk with long-term use
Use cautiously in elderly patients
Monitor liver and kidney function
Avoid in patients with history of GI bleeding
Not for long-term uncontrolled use
Side Effects:
Common:
Headache
Dizziness
Nausea
Dyspepsia
Uncommon:
Edema
Hypertension
Abdominal pain
Serious (Rare):
Cardiovascular events (MI, stroke)
GI bleeding
Liver toxicity
Severe skin reactions
Clinical Note:
ETDOL-P combines the selective anti-inflammatory action of etoricoxib (COX-2 inhibitor) with the analgesic effect of paracetamol, providing fast, effective, and targeted pain relief with improved gastrointestinal tolerability compared to traditional NSAIDs.

ETDOL-TH Tablets
Generic Name:
Etoricoxib 90 mg + Thiocolchicoside 4 mg
Therapeutic Group:
Analgesic, Anti-inflammatory & Muscle Relaxant
Drug Category:
Selective COX-2 Inhibitor (NSAID) + Centrally Acting Muscle Relaxant
Content / Composition:
Each film-coated tablet contains:
Etoricoxib ………………… 90 mg
Thiocolchicoside ……… 4 mg
Excipients ………………… q.s.
Indications:
ETDOL-TH is indicated for:
Acute musculoskeletal pain
Low back pain (Lumbago)
Cervical and lumbar spondylosis
Muscle spasm associated with spine disorders
Sciatica
Post-traumatic muscle spasm
Orthopedic conditions with inflammation and stiffness
Dosage:
Adults: 1 tablet once daily or as directed by physician
Duration: Short-term use (usually 5–7 days)
Do not exceed recommended duration due to muscle relaxant safety profile
Contraindications:
Hypersensitivity to etoricoxib, thiocolchicoside, or NSAIDs
Active peptic ulcer or GI bleeding
Severe hepatic or renal impairment
Pregnancy and lactation
Women of childbearing potential not using contraception (thiocolchicoside warning)
Neuromuscular disorders (e.g., epilepsy risk)
Administration:
Oral use, preferably after food
Swallow with sufficient water
Avoid alcohol during treatment
Use strictly under medical supervision
Drug Interactions:
Anticoagulants → Increased bleeding risk
CNS depressants → Increased sedation
Other NSAIDs → Increased GI toxicity
Antihypertensives → Reduced effect
Drugs lowering seizure threshold → Increased risk (thiocolchicoside)
Compatibility:
Ideal for patients with pain + muscle spasm combination
Suitable for orthopedic and neurological pain conditions
Can be combined with physiotherapy for better outcomes
Stability / Storage:
Store below 25°C
Protect from light and moisture
Keep out of reach of children
Precautions:
Use for short duration only (important for thiocolchicoside safety)
Monitor liver and kidney function
Use cautiously in elderly patients
Avoid prolonged use due to cardiovascular risk (etoricoxib)
Not recommended in chronic long-term therapy
Side Effects:
Common:
Dizziness
Drowsiness
Nausea
Gastric discomfort
Uncommon:
Diarrhea
Edema
Increased blood pressure
Serious (Rare):
Seizures (thiocolchicoside-related)
GI bleeding
Cardiovascular events
Hepatic dysfunction
Clinical Note:
ETDOL-TH provides a dual-action approach by combining:
Etoricoxib → potent anti-inflammatory & pain relief
Thiocolchicoside → effective muscle relaxation
This combination is highly effective for acute painful muscle spasm conditions, delivering fast relief, improved mobility, and reduced stiffness.

SBDOL-TH Tablets
Generic Name:
Aceclofenac 100 mg + Paracetamol 325 mg + Thiocolchicoside 4 mg
Therapeutic Group:
Analgesic, Anti-inflammatory & Muscle Relaxant
Drug Category:
NSAID (Phenylacetic Acid Derivative) + Non-Opioid Analgesic + Centrally Acting Muscle Relaxant
Content / Composition:
Each film-coated tablet contains:
Aceclofenac ………………… 100 mg
Paracetamol ………………… 325 mg
Thiocolchicoside ………… 4 mg
Excipients …………………… q.s.
Indications:
SBDOL-TH is indicated for:
Acute musculoskeletal pain
Low back pain (Lumbago)
Cervical & lumbar spondylosis
Muscle spasm associated with spine disorders
Sciatica
Post-traumatic pain & inflammation
Orthopedic conditions with stiffness and muscle spasm
Rheumatic pain with muscle tightness
Dosage:
Adults: 1 tablet once or twice daily after food
Duration: Short-term use (usually 5–7 days)
Use lowest effective dose for shortest duration
Contraindications:
Hypersensitivity to NSAIDs, paracetamol, or thiocolchicoside
Active peptic ulcer or GI bleeding
Severe hepatic or renal impairment
Pregnancy and lactation
History of NSAID-induced asthma
Women of childbearing age not using contraception (thiocolchicoside restriction)
Seizure disorders (caution)
Administration:
Oral use after meals
Swallow whole with water
Avoid alcohol
Do not combine with other NSAIDs
Drug Interactions:
Anticoagulants → Increased bleeding risk
Other NSAIDs → GI toxicity
Corticosteroids → Increased ulcer risk
CNS depressants → Increased sedation
Hepatotoxic drugs → Increased liver risk
Antihypertensives → Reduced effect
Compatibility:
Ideal for pain + inflammation + muscle spasm combination
Suitable for orthopedic and trauma-related conditions
Works well alongside physiotherapy
Stability / Storage:
Store below 25°C
Protect from light and moisture
Keep out of reach of children
Precautions:
Short-term use recommended (thiocolchicoside safety)
Monitor liver function (paracetamol)
Use cautiously in elderly patients
Avoid prolonged NSAID use (CV & GI risk)
Not recommended for chronic long-term therapy
Side Effects:
Common:
Gastric irritation
Nausea
Dizziness
Drowsiness
Uncommon:
Diarrhea
Edema
Elevated liver enzymes
Serious (Rare):
GI bleeding
Hepatotoxicity
Cardiovascular events
Seizures (thiocolchicoside-related)
Clinical Note:
SBDOL-TH is a triple-action advanced formula combining:
Aceclofenac → Potent anti-inflammatory effect
Paracetamol → Rapid pain relief
Thiocolchicoside → Effective muscle relaxation
This combination delivers fast, comprehensive relief in conditions involving pain, inflammation, and muscle spasm, improving mobility and patient recovery.